Butterfly Network stock surges 15% after being named to TIME's World's Top HealthTech Companies list.
ByAinvest
Friday, Sep 19, 2025 4:10 am ET1min read
BFLY--
The recognition comes on the heels of Butterfly Network’s iQ3 device winning Best Medical Technology at the 2024 Prix Galien USA Awards. Joseph DeVivo, President, CEO, and Chairman of Butterfly Network, expressed pride in the company’s inclusion on the TIME list, emphasizing their dedication to making ultrasound technology more accessible [1].
Despite a 39.42% loss for 2025, BFLY has shown strong momentum in the past month, with a 36.96% gain. The stock’s price peaked at $4.82 in 2025 on February 18, but it closed at $1.89 on September 12, reflecting a decrease of 60.7% [1]. BFLY trades within a 52-week range of $1.66 to $13.56, with a market capitalization of $475.79 million and an average daily volume of 2.91 million shares [1].
The digital healthcare sector continues to evolve, with companies like VideaHealth also being recognized for their innovations. VideaHealth, a leader in AI-powered dental solutions, was named to TIME’s World’s Top HealthTech Companies 2025 list in the Diagnostics category with an Outstanding ranking [2]. This recognition underscores the growing impact of AI in transforming healthcare.
Butterfly Network Inc. remains focused on its innovation strategy, with the iQ3 device driving growth prospects. The company’s recent achievements highlight its commitment to advancing healthcare technology and making it more accessible to patients.
Butterfly Network Inc. (BFLY) shares surged 14.81% in after-hours trading, following a 15.95% gain during regular trading. The company was named to TIME's first-ever list of the World's Top HealthTech Companies for 2025. BFLY's iQ3 device won Best Medical Technology at the 2024 Prix Galien USA Awards. The stock has a 39.42% loss for 2025, but a 36.96% gain in the past month.
Butterfly Network Inc. (BFLY) shares surged 14.81% in after-hours trading on September 12, 2025, following a 15.95% gain during regular trading. The Massachusetts-based company was named to TIME’s inaugural list of the World’s Top HealthTech Companies for 2025, highlighting its innovation and impact in the healthcare technology sector [1].The recognition comes on the heels of Butterfly Network’s iQ3 device winning Best Medical Technology at the 2024 Prix Galien USA Awards. Joseph DeVivo, President, CEO, and Chairman of Butterfly Network, expressed pride in the company’s inclusion on the TIME list, emphasizing their dedication to making ultrasound technology more accessible [1].
Despite a 39.42% loss for 2025, BFLY has shown strong momentum in the past month, with a 36.96% gain. The stock’s price peaked at $4.82 in 2025 on February 18, but it closed at $1.89 on September 12, reflecting a decrease of 60.7% [1]. BFLY trades within a 52-week range of $1.66 to $13.56, with a market capitalization of $475.79 million and an average daily volume of 2.91 million shares [1].
The digital healthcare sector continues to evolve, with companies like VideaHealth also being recognized for their innovations. VideaHealth, a leader in AI-powered dental solutions, was named to TIME’s World’s Top HealthTech Companies 2025 list in the Diagnostics category with an Outstanding ranking [2]. This recognition underscores the growing impact of AI in transforming healthcare.
Butterfly Network Inc. remains focused on its innovation strategy, with the iQ3 device driving growth prospects. The company’s recent achievements highlight its commitment to advancing healthcare technology and making it more accessible to patients.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet